Obesity and weight health articles covering diabetes risk, GLP-1 medicines, lifestyle support, metabolic health, stigma, and long-term care questions.Weight is influenced by biology, environment, medicines, sleep, stress, and access to care. Effective support should be respectful, evidence-aware, and individualized.
An ENDO 2026 real-world study linked semaglutide with fewer bone fractures than several other weight-loss medicines in adults with type 2 diabetes. The finding is interesting, but it does not prove semaglutide prevents fractures.
Phase 3 retatrutide data in recent-onset type 2 diabetes showed A1C lowering and weight loss. The drug remains investigational and is not FDA-approved.
Retatrutide: A New Horizon in Diabetes and Obesity Management: evidence-based guidance reviewed against current NICE and ADA recommendations. Practical.
